ASX copper stocks have recorded 3 big hits this week
Nick Sundich, November 4, 2022
ASX copper stocks have not been as popular with investors as lithium stocks recently. Copper has been plagued by China’s COVID zero policy and rising interest rates. But there have been some notable hits made by ASX copper explorers this week.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
Norfolk Metals leads the charge
Tasmanian-focused explorer Norfolk Metals (ASX:NFL) yesterday reported the intersection of native copper in the maiden drill test at its Roger River Project.
These were not formal assay results, these are coming in December. But the company did intersect visible copper and, in doing so in the first drilling hole, shareholders hope that further results will continue to deliver.
Other ASX copper hits this week
Another solid result from an ASX copper stock came from American West (ASX:AW1). The Canadian focused explorer recorded assay results of 19m @ 2.08%, including 2m at 15.98% copper.
And this morning, Cosmo Metals (ASX:CMO) reported results from its Mt. Venn project in Western Australia: 13m @ 0.46% copper, including 1m @ 1.27% copper. Typically, any copper grade below 1.3% is considered lower grade. But it appears shareholders are willing to forgive this given WA’s lower sovereign risk.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
No credit card needed and the trial expires automatically.
Blog Categories
Get Our Top 5 ASX Stocks for FY25
Recent Posts
Analysts aren’t optimistic about iron ore prices in 2025, will they be right and what will it mean for iron ore stocks?
In which direction will iron ore prices in 2025 go? Chinese trade data would suggest upwards, and indeed prices jumped…
Paradigm Biopharmaceuticals’ flagship drug Zilosul will be in Phase 3 in 2025
Paradigm Biopharmaceuticals (ASX:PAR) has been listed for nearly a decade with the goal of bringing its flagship drug pentosan polysulfate…
Findi (ASX:FND): Its quadrupled in 12 months off the back of financial services in India
Until Findi (ASX:FND) came along, there were practically no ASX companies making money from India (or at least not many…